Journal of Neural Transmission

, Volume 115, Issue 4, pp 641–645 | Cite as

Evidence for effectiveness of botulinum toxin for hyperhidrosis

Article

Summary

Hyperhidrosis refers to excessive and uncontrollable sweating beyond that is required to return body temperature to normal. Although a broad spectrum of treatment modalities are available including topical and systemic therapies, iontophoresis, and surgical interventions, their efficacy are usually short-term or are associated with unacceptable side effects.

Recently, chemodenervation using botulinum toxin has emerged as a safe and effective treatment for both primary palmar and axillary hyperhidrosis in several clinical trials. In this article, we utilized the scale developed by the Therapeutics and Technology Assessment (TTA) subcommittee of the American Academy of Neurology evaluating current evidence supporting the use of botulinum toxin for the treatment of primary focal hyperhidrosis. As a result, there is a strong evidence to support the efficacy of botulinum toxin type A in axillary (Level A evidence) and palmar (Level B evidence) hyperhidrosis.

Keywords: Botulinum toxin; hyperhidriosis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baumann, L, Slezinger, A, Halem, M, Vujevich, J, Mallin, K, Charles, C,  et al. 2005Double-blind, randomized, placebo-controlled pilot study of the safety and efficacy of Myobloc (botulinum toxin type B) for the treatment of palmar hyperhidrosisDermatol Surg31263270PubMedCrossRefGoogle Scholar
  2. Bhidayasiri, R, Truong, DD 2005Expanding use of botulinum toxinJ Neurol Sci23519PubMedCrossRefGoogle Scholar
  3. Braune, C, Erbguth, F, Birklein, F 2001Dose thresholds and duration of the local anhidrotic effect of botulinum toxin injections: measured by sudometryBr J Dermatol144111117PubMedCrossRefGoogle Scholar
  4. Bushara, KO, Park, DM, Jones, JC, Schutta, HS 1996Botulinum toxin – a possible new treatment for axillary hyperhidrosisClin Exp Dermatol21276278PubMedCrossRefGoogle Scholar
  5. Campanati, A, Penna, L, Guzzo, T,  et al. 2003Quality-of-life assessment in patients with hyperhidrosis before and after treatment with botulinum toxin: results of an open-label studyClin Ther25298308PubMedCrossRefGoogle Scholar
  6. Cheshire, WP 1996Subcutaneous botulinum toxin type A inhibits regional sweating: an individual observationClin Auton Res6123124PubMedCrossRefGoogle Scholar
  7. Edlund W, Gronseth G, So Y, Franklin G (2004) Subcommittee for the Quality Standards Subcommittee and the Therapeutics and Technology Assessment Subcommittee. Clinical Practice Guideline Process Manual. American Academy of Neurology, MinneapolisGoogle Scholar
  8. Glaser, DA 2004Treatment of axillary hyperhidrosis by chemodenervation of sweat glands using botulinum toxin type AJ Drugs Dermatol3627631PubMedGoogle Scholar
  9. Hamm, H, Naumann, MK, Kowalski, JW, Kutt, S, Kozma, C, Teale, C 2006Primary focal hyperhidrosis: disease characteristics and functional impairmentDermatology212343353PubMedCrossRefGoogle Scholar
  10. Heckmann, M, Ceballos-Baumann, AO, Plewig, G 2001Botulinum toxin A for axillary hyperhidrosis (excessive sweating)N Engl J Med344488493PubMedCrossRefGoogle Scholar
  11. Heckmann, M, Teichmann, B, Pause, BM, Plewig, G 2003Amelioration of body odor after intracutaneous axillary injection of botulinum toxinArch Dermatol1395759PubMedCrossRefGoogle Scholar
  12. Hornberger, J Grimes, K Naumann, M for the Multi-specialty Working Group on the Recognition, Diagnosis, and Treatment of Primary Focal Hyperhidrosis et al. 2004Recognition, diagnosis, treatment of primary focal hyperhidrosisJ Am Acad Dermatol51274286PubMedCrossRefGoogle Scholar
  13. Karamfilov, T, Konrad, H, Karte, K, Wollina, U 2000Lower relapse rate of botulinum toxin A therapy for axillary hyperhidrosis by dose increaseArch Dermatol136487490PubMedCrossRefGoogle Scholar
  14. Kowalski JW, Eadie N, Daggett S, et al (2004) Validity and reliability of the hyperhidrosis disease severity scale (HDSS). The 62nd Annual Meeting of the American Academy of Dermatology, Washington, DCGoogle Scholar
  15. Lear, W, Kessler, E, Solish, N, Glaser, DA 2007An epidemiological study of hyperhidrosisDermatol Surg33S69S75PubMedCrossRefGoogle Scholar
  16. Lillis, PJ, Coleman, WPI 1990Liposuction for treatment of axillary hyperhidrosisDermatol Clin8479482PubMedGoogle Scholar
  17. Lin, T, Wang, N, Huang, L 2001Pitfalls and complication avoidance associated with transthoracic endoscopic sympathectomy for primary hyperhidrosis (analysis of 2200 cases)Int J Surg Invest2377385Google Scholar
  18. Lowe, N, Campanati, A, Bodokh, I, Cliff, S, Jaen, P, Kreyden, O,  et al. 2004The place of botulinum toxin type A in the treatment of focal hyperhidrosisBr J Dermatol15111151122PubMedCrossRefGoogle Scholar
  19. Lowe, NJ, Yamauchi, PS, Lask, GP, Patnaik, R, Iyer, S 2002Efficacy and safety of botulinum toxin type a in the treatment of palmar hyperhidrosis: a double-blind, randomized, placebo-controlled studyDermatol Surg28822827PubMedCrossRefGoogle Scholar
  20. Lowe, NJ, Glaser, DA, Eadie, N, Daggett, S, Kowalski, JW, Lai, PY 2007Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safetyJ Am Acad Dermatol56604611PubMedCrossRefGoogle Scholar
  21. Naumann, M 2001Evidence-based medicine: botulinum toxin in focal hyperhidrosisJ Neurol2483133PubMedCrossRefGoogle Scholar
  22. Naumann, M, Flachenecker, P, Brocker, EB, Toyka, KV, Reiners, K 1997Botulinum toxin for palmar hyperhidrosisLancet349252PubMedCrossRefGoogle Scholar
  23. Naumann, M, Lowe, NJ 2001Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trialBMJ323596599PubMedCrossRefGoogle Scholar
  24. Naumann, M, Lowe, NJ, Kumar, CR, Hamm, H 2003Botulinum toxin type a is a safe and effective treatment for axillary hyperhidrosis over 16 months: a prospective studyArch Dermatol139731736PubMedCrossRefGoogle Scholar
  25. Naumann, MK, Hamm, H, Lowe, NJ 2002Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trialBr J Dermatol14712181226PubMedCrossRefGoogle Scholar
  26. Odderson, IR 2002Long-term quantitative benefits of botulinum toxin type A in the treatment of axillary hyperhidrosisDermatol Surg28480483PubMedCrossRefGoogle Scholar
  27. Proebstle, TM, Schneiders, V, Knop, J 2002Gravimetrically controlled efficacy of sucorial curettage: a prospective study for treatment of axillary hyperhidrosisDermatol Surg2810221026PubMedCrossRefGoogle Scholar
  28. Quinton, PM 1983Sweating and its disordersAnn Rev Med34429520PubMedCrossRefGoogle Scholar
  29. Reinauer, S, Neusser, A, Schauf, G, Holzle, E 1993Iontophoresis with alternating current and direct current offer (AC/DC iontophoresis): a new approach for the treatment of hyperhidrosisBr J Dermatol129166169PubMedCrossRefGoogle Scholar
  30. Ro, KM, Cantor, RM, Lange, KL, Ahn, SS 2002Palmar hyperhidrosis: evidence of genetic transmissionJ Vasc Surg35382386PubMedCrossRefGoogle Scholar
  31. Rompel, R, Scholz, S 2001Subcutaneous curettage vs injection of botulinum toxin A for treatment of axillary hyperhidrosisJ Eur Acad Dermatol Venereol15207211PubMedCrossRefGoogle Scholar
  32. Saadia, D, Voustianiouk, A, Wang, AK, Kaufmann, H 2001Botulinum toxin type A in primary palmar hyperhidrosis: randomized, single-blind, two-dose studyNeurology5720952099PubMedGoogle Scholar
  33. Sato, K, Kang, WH, Saga, K, Sato, KT 1989aBiology of sweat glands and their disorders. I. Normal sweat gland functionJ Am Acad Dermatol20537563Google Scholar
  34. Sato, K, Kang, WH, Saga, K, Sato, KT 1989bBiology of sweat glands and their disorders. II. Disorders of sweat gland functionJ Am Acad Dermatol20713726CrossRefGoogle Scholar
  35. Simonetta Moreau, M, Cauhepe, C, Magues, JP, Senard, JM 2003A double-blind, randomized, comparative study of Dysport vs. Botox in primary palmar hyperhidrosisBr J Dermatol14910411045PubMedCrossRefGoogle Scholar
  36. Solish, N, Benohanian, A, Kowalski, JW 2005Hyperhidrosis obotCDSGoH-RQoLiPA. Prospective open-label study of botulinum toxin type A in patients with axillary hyperhidrosis: effects on functional impairment and quality of lifeDermatol Surg31405413PubMedCrossRefGoogle Scholar
  37. Stolman, LP 1998Treatment of hyperhidrosisDermatol Clin16863867PubMedCrossRefGoogle Scholar
  38. Strutton, DR, Kowalski, JW, Glaser, DA, Stang, PE 2004US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national surveyJ Am Acad Dermatol51241248PubMedCrossRefGoogle Scholar
  39. Swartling, C, Naver, H, Lindberg, M 2001Botulinum A toxin improves life quality in severe primary focal hyperhidrosisEur J Neurol8247252PubMedCrossRefGoogle Scholar
  40. Talarico-Filho, S, Mendonca do Nascimento, M, Sperandeo de Macedo, F, de Sanctis Pecora, C 2007A double-blind, randomized, comparative study of two type A botulinum toxins in the treatment of primary axillary hyperhidrosisDermatol Surg33S44S50PubMedCrossRefGoogle Scholar
  41. Tan, SR, Solish, N 2002Long-term efficacy and quality of life in the treatment of focal hyperhidrosis with botulinum toxin type ADermatol Surg28495499PubMedCrossRefGoogle Scholar
  42. Tu, YR, Li, X, Lin, M, Lai, FC, Li, YP, Chen, JF,  et al. 2007Epidemiological survey of primary palmar hyperhidrosis in adolescent in Fuzhou of People’s Republic of ChinaEur J Cardiothorac Surg31737739PubMedCrossRefGoogle Scholar
  43. Ware, JE, Kosinski, M, Keller, SD 1996A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validityMed Care34220233PubMedCrossRefGoogle Scholar
  44. Zacherl, J, Huber, ER, Imhof, M,  et al. 1998Long-term results of 630 thoracoscopic sympathectomies for primary hyperhidrosis: the Viena experienceEur J Surg Suppl5804346PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Chulalongkorn Comprehensive Movement Disorders CenterChulalongkorn Univerisity HospitalBangkokThailand
  2. 2.Department of NeurologyDavid Geffen School of Medicine at UCLALos AngelesUSA
  3. 3.The Parkinson’s and Movement Disorder InstituteFountain ValleyUSA

Personalised recommendations